Nixon Peabody Trust Co. Sells 1,036 Shares of Eli Lilly and Company $LLY

Nixon Peabody Trust Co. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,522 shares of the company’s stock after selling 1,036 shares during the period. Eli Lilly and Company makes up 1.5% of Nixon Peabody Trust Co.’s portfolio, making the stock its 16th biggest position. Nixon Peabody Trust Co.’s holdings in Eli Lilly and Company were worth $19,905,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its position in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. 10Elms LLP raised its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the period. Finally, Miller Global Investments LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $33,000. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. Zacks Research cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Morgan Stanley reissued an “overweight” rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 1st. Bank of America cut their target price on shares of Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Rothschild & Co Redburn upped their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,220.37.

Eli Lilly and Company Stock Performance

LLY opened at $1,066.59 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 37.89, a PEG ratio of 1.13 and a beta of 0.48. The company has a fifty day moving average of $942.87 and a 200 day moving average of $1,003.77. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.